

Resource Summary Report

Generated by [dkNET](#) on Sep 5, 2026

KYSE-30

RRID:CVCL_1351

Type: Cell Line

Proper Citation

RRID:CVCL_1351

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1351

Proper Citation: RRID:CVCL_1351

Description: Cell line KYSE-30 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Esophageal squamous cell carcinoma

Defining Citation: [PMID:1728357](#), [PMID:7913084](#), [PMID:8575860](#), [PMID:9033652](#), [PMID:11092977](#), [PMID:11520067](#), [PMID:12963126](#), [PMID:15172977](#), [PMID:16045545](#), [PMID:16364037](#), [PMID:20215515](#), [PMID:21191746](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#)

Comments: Population: Japanese., Part of: KuDOS 95 cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KYSE-30

Synonyms: Kyse-30, KYSE 30, KYSE30, Kyse30, KYSE0030

Cross References: BTO:BTO_0004461, CLO:CLO_0007132, EFO:EFO_0002223, CLDB:cl3073, CLDB:cl3074, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, BCRJ:0404, BioGRID_ORCS_Cell_line:411, BioSample:SAMN03471050, BioSample:SAMN03471648, BioSample:SAMN03473314, BioSample:SAMN10988382, cancercellines:CVCL_1351, Cell_Model_Passport:SIDM00015, CGH-DB:274-1, CGH-DB:9223-4, ChEMBL-

Cells:CHEMBL4513120, ChEMBL-Targets:CHEMBL4513130, CLS:305094, Cosmic:801333, Cosmic:918521, Cosmic:1123333, Cosmic:1298221, Cosmic:1339921, Cosmic:1581068, Cosmic:1876249, Cosmic:2267697, Cosmic:2395004, Cosmic:2650627, Cosmic:2698430, DepMap:ACH-000777, DSMZ:ACC-351, DSMZCellDive:ACC-351, ECACC:94072011, EGA:EGAS00001000610, GDSC:1298221, GEO:GSM827542, GEO:GSM887251, GEO:GSM888326, GEO:GSM1374609, GEO:GSM1374610, GEO:GSM1374611, IARC_TP53:7691, ICLC:HTL97022, IGRhCellID:KYSE30, JCRB:JCRB0188, LiGeA:CCL_634, LINCSP_LDP:LCL-1553, NCBI_Iran:C584, PharmacDB:KYSE30_806_2019, Progenetix:CVCL_1351, PubChem_Cell_line:CVCL_1351, Ubigen:YC-C054, Wikidata:Q54900823

ID: CVCL_1351

Record Creation Time: 20220427T220712+0000

Record Last Update: 20260904T014518+0000

Ratings and Alerts

No rating or validation information has been found for KYSE-30.

No alerts have been found for KYSE-30.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 295 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Liao H, et al. (2026) Ectopic CD11c Drives SMAD3-Mediated Aberrant Antigen Presentation and Epithelial-Mesenchymal Transition in Esophageal Squamous Cell Carcinoma. Cancer communications (London, England), 46, 0014.

Jakobsen JS, et al. (2026) Sym024 Interacts with a Unique Epitope on the CD73 Homodimer, Favoring Effective Bivalent Binding to Improve Anti-PD-1 Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(6), 1120.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. Molecular cell.

Yuan H, et al. (2026) Clinofibrate Disrupts the SNORA80B/YTHDC1-Driven M6A Modification to Suppress Cholesterol Metabolism and Cisplatin Resistance in ESCC. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(3), e09574.

Chen Y, et al. (2026) PDIA6 promotes the cell proliferation of ESCC by enhancing the disulfide bond formation in TRAF4. *Cellular & molecular biology letters*, 31(1).

Zhu L, et al. (2026) A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer. *Cancer discovery*, 16(7), 1360.

Ma J, et al. (2026) Alcohol-Induced Metabolic Stress Sensed by m6A-Modified ChREBP Drives Immune Evasion in Esophageal Carcinogenesis. *Cancer research*.

Wu J, et al. (2026) A Noncanonical RNA-Binding Function of NQO1 Drives Angiogenesis in Esophageal Squamous Cell Carcinoma via Extracellular Vesicle-Mediated AGRN Transfer. *Cancer research*, 86(12), 2951.

Chen RX, et al. (2026) NIPAL1 Drives a Metabolic-Epigenetic Feedback Loop to Promote Lactate-Mediated Immune Evasion in Esophageal Cancer. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(29), e20055.

Han T, et al. (2026) ID4 Suppresses Proliferation and Macrophage Polarization in Esophageal Carcinoma through Interaction with TCF4. *Molecular cancer research : MCR*, 24(6), 458.

Peng P, et al. (2026) Lactylome Reprogramming Mediates Therapeutic Response and Adaptation to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. *Molecular & cellular proteomics : MCP*, 25(5), 101561.

Yu Z, et al. (2026) Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer. *Journal for immunotherapy of cancer*, 14(5).

Ding Y, et al. (2025) SRPK1 Activation Facilitates Gli3S664 Phosphorylation and Promotes Metastasis in Esophageal Squamous Cell Carcinoma. *Molecular carcinogenesis*, 64(7), 1168.

Zou G, et al. (2025) Role of PLEKHA7 in promoting radioresistance in esophageal cancer cells via the inhibition of cuproptosis. *Journal of thoracic disease*, 17(6), 4219.

Wang HL, et al. (2025) Anovel anti-B7-H3 nanobody and its DM1 conjugate with marked anti-tumor activity against esophageal squamous cell carcinoma. *International journal of biological macromolecules*, 322(Pt 4), 147025.

Chen RX, et al. (2025) m6A-mediated circG3BP1 translocation to stress granules promotes nucleation and senescence-linked chemoresistance. *Cell reports*, 44(10), 116375.

Bai L, et al. (2025) CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing. *Journal of nanobiotechnology*, 24(1), 102.

Lin J, et al. (2025) NUDT21 lactylation reprograms alternative polyadenylation to promote cuproptosis resistance. *Cell discovery*, 11(1), 52.

Wang KH, et al. (2025) RNF185 promotes esophageal squamous cell carcinoma progression by regulating BAK1 ubiquitination and activating the cGAS-STING-IRF3 pathway. *European journal of medical research*, 30(1), 1139.

Han L, et al. (2024) Periplcymarin targets glycolysis and mitochondrial oxidative phosphorylation of esophageal squamous cell carcinoma: Implication in anti-cancer therapy. *Phytomedicine : international journal of phytotherapy and phytopharmacology*, 128, 155539.